2013
DOI: 10.5489/cuaj.1165
|View full text |Cite
|
Sign up to set email alerts
|

Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma

Abstract: It has been reported that patients with bladder cancer have widely varying paraneoplastic consequences, including metabolic, dermatologic, myopathic and neurologic disturbances. We report a case of a 52-year-old man with advanced transitional cell carcinoma and liver metastases, who developed a severe coagulopathy following robotic radical cystoprostatectomy due to circulating heparin-like substances prior to onset of liver failure. Heparin-like anticoagulant production is a rare paraneoplastic effect document… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
7
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 16 publications
0
7
0
Order By: Relevance
“…HLE has been previously demonstrated in three clinical settings: acute liver failure during liver disease and liver transplantation [ 10 , 11 ], sepsis/SIRS [ 12 ], and cancer [ 13 ]. The mechanisms leading to the HLE are multifactorial, and include (i) failure of the liver to clear the circulating GAGs during acute liver failure [ 14 ], (ii) neutrophil-mediated injury of the hepatocytes that can release heparin sulphate [ 15 ], and (iii) the direct release of GAGs from the endothelial surface and the mast cells during sepsis/SIRS [ 15 ].…”
Section: Discussionmentioning
confidence: 99%
“…HLE has been previously demonstrated in three clinical settings: acute liver failure during liver disease and liver transplantation [ 10 , 11 ], sepsis/SIRS [ 12 ], and cancer [ 13 ]. The mechanisms leading to the HLE are multifactorial, and include (i) failure of the liver to clear the circulating GAGs during acute liver failure [ 14 ], (ii) neutrophil-mediated injury of the hepatocytes that can release heparin sulphate [ 15 ], and (iii) the direct release of GAGs from the endothelial surface and the mast cells during sepsis/SIRS [ 15 ].…”
Section: Discussionmentioning
confidence: 99%
“…Pathophysiologic mechanisms leading to DIC in individuals with solid tumor are not fully understood. Solid tumor cells may express procoagulant molecules, including tissue factor and cancer procoagulant, and fibrinolytic proteins, and may be associated with paraneoplastic production of heparin‐like anticoagulant . Furthermore, proinflammatory cytokines, such as IL‐6 and TNFα, have been demonstrated to contribute to DIC in cancer patients .…”
Section: Discussionmentioning
confidence: 99%
“…Due to its uncommon occurrence, the treatment of HLArelated bleeding disorders is far from clear; the administration of protamine is anecdotal [9], and its efficacy equivocal [7,10,11].…”
Section: Discussionmentioning
confidence: 98%
“…Heparin-like anticoagulants have been described in a number of other diseases, including transitional cell carcinomas [6,7], breast cancer [8], multiple myeloma [9], systemic mastocytosis [10] and hepatocellular carcinoma [11].…”
Section: Discussionmentioning
confidence: 99%